Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

5.8K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

5.0K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

FGFR inhibitor resistance in cervical cancer: a role for integrin α2 and mTOR signalling.

Frontiers in cell and developmental biology·2026
Same author

Polymeric Microneedles: Advancing Potential Through Innovative Manufacturing, Polymer Design, and Characterization Techniques.

Current pharmaceutical design·2025
Same author

Development and Characterization of Three Novel FGFR Inhibitor Resistant Cervical Cancer Cell Lines to Help Drive Cervical Cancer Research.

International journal of molecular sciences·2025
Same author

FGF signalling facilitates cervical cancer progression.

The FEBS journal·2021
Same author

Biological Significance and Targeting of the FGFR Axis in Cancer.

Cancers·2021
Same author

3D Organotypic Culture Model to Study Components of ERK Signaling.

Methods in molecular biology (Clifton, N.J.)·2016

Related Experiment Video

Updated: Jul 19, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.2K

Dysregulated Signalling Pathways Driving Anticancer Drug Resistance.

Nauf Bou Antoun1, Athina-Myrto Chioni1

  • 1School of Life Sciences Pharmacy and Chemistry, Biomolecular Sciences Department, Kingston University London, Kingston-upon-Thames KT1 2EE, UK.

International Journal of Molecular Sciences
|August 12, 2023
PubMed
Summary

Cancer drug resistance, both intrinsic and acquired, hinders treatment success. Understanding resistance mechanisms is crucial for developing new cancer therapies and improving patient outcomes.

Keywords:
JAK/STAT pathwayPI3K/Akt/mTOR pathwayRAS/RAF/MAPK/ERK signallingWnt/β-catenin pathwaycancerdrug resistancesignalling pathwaystumourigenesis

More Related Videos

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.6K
Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.0K

Related Experiment Videos

Last Updated: Jul 19, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.2K
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.6K
Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.0K

Area of Science:

  • Oncology
  • Cancer Biology
  • Pharmacology

Background:

  • Cancer remains a leading global cause of death, with drug resistance significantly limiting therapeutic success.
  • Intrinsic and acquired resistance mechanisms are key drivers of cancer relapse and treatment failure.
  • Numerous factors, including tumor microenvironment and signaling pathways, regulate cancer progression and drug resistance.

Purpose of the Study:

  • To provide a comprehensive overview of intrinsic and acquired cancer drug resistance mechanisms.
  • To highlight key signaling pathways involved in cancer drug resistance.
  • To underscore the importance of understanding these mechanisms for future cancer treatment strategies.

Main Methods:

  • This review synthesizes recent research on cancer drug resistance.
  • It examines various factors regulating tumorigenesis and resistance.
  • Key signaling pathways implicated in resistance are discussed.

Main Results:

  • Cancer cells develop intrinsic and acquired resistance through diverse mechanisms.
  • Factors like tumor microenvironment, heterogeneity, and genetic alterations play critical roles.
  • Signaling pathways such as TGF-β, EGFR, PI3K/Akt/mTOR, and Wnt are pivotal in mediating resistance.

Conclusions:

  • A deeper understanding of cancer drug resistance pathways is essential for advancing cancer treatment.
  • Identifying alternative routes utilized by cancer cells is key to overcoming resistance.
  • This knowledge will guide the development of more effective therapeutic strategies to improve patient outcomes.